cilostazol has been researched along with Cognitive Decline in 10 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "A systematic review and meta-analysis of unconfounded randomized controlled trials of cilostazol to prevent stroke, cognitive decline, or radiological small vessel disease lesion progression." | 9.05 | Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis. ( Appleton, JP; Bath, PM; Blair, GW; Chappell, FM; Doubal, F; McHutchison, C; Wardlaw, JM, 2020) |
| "In this randomized clinical trial, cilostazol was well tolerated, although it did not prevent cognitive decline." | 5.69 | Efficacy and Safety of Cilostazol in Mild Cognitive Impairment: A Randomized Clinical Trial. ( Aso, T; Fukushima, M; Fukuyama, H; Hattori, Y; Ihara, M; Kagimura, T; Kakuta, C; Kakuta, R; Kanki, R; Kawabata, N; Kitaguchi, H; Kojima, S; Kowa, H; Maki, T; Mizuno, T; Nagatsuka, K; Nakaoku, Y; Ohtani, R; Oishi, N; Oka, N; Saito, S; Shindo, A; Shindo, K; Sudoh, S; Suzuki, K; Tachibana, H; Taguchi, A; Takahashi, R; Takahashi, Y; Taketsuna, M; Tomimoto, H; Tonomura, S; Washida, K; Yamamoto, H; Yamamoto, K; Yamamoto, Y; Yasuno, F, 2023) |
| "Of the 1534 ischemic stroke patients who randomly assigned to aspirin or cilostazol treatment with best medical therapy by the PICASSO (PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage) trial, 1240 with baseline mini-mental state examination (MMSE) scores were analysed retrospectively." | 5.34 | Post-stroke cognitive impairment as an independent predictor of ischemic stroke recurrence: PICASSO sub-study. ( Hong, KS; Kang, DW; Kwon, HS; Kwon, SU; Lee, D; Lee, EJ; Lee, JS; Lee, MH; Lim, JS; Oh, MS; Yu, KH; Yu, S, 2020) |
| "A systematic review and meta-analysis of unconfounded randomized controlled trials of cilostazol to prevent stroke, cognitive decline, or radiological small vessel disease lesion progression." | 5.05 | Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis. ( Appleton, JP; Bath, PM; Blair, GW; Chappell, FM; Doubal, F; McHutchison, C; Wardlaw, JM, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 6 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chien, CF | 1 |
| Huang, LC | 1 |
| Li, KY | 1 |
| Yang, YH | 1 |
| Saito, S | 1 |
| Suzuki, K | 1 |
| Ohtani, R | 1 |
| Maki, T | 1 |
| Kowa, H | 1 |
| Tachibana, H | 1 |
| Washida, K | 1 |
| Kawabata, N | 1 |
| Mizuno, T | 1 |
| Kanki, R | 1 |
| Sudoh, S | 1 |
| Kitaguchi, H | 1 |
| Shindo, K | 1 |
| Shindo, A | 1 |
| Oka, N | 1 |
| Yamamoto, K | 1 |
| Yasuno, F | 1 |
| Kakuta, C | 1 |
| Kakuta, R | 1 |
| Yamamoto, Y | 1 |
| Hattori, Y | 1 |
| Takahashi, Y | 1 |
| Nakaoku, Y | 1 |
| Tonomura, S | 1 |
| Oishi, N | 1 |
| Aso, T | 1 |
| Taguchi, A | 2 |
| Kagimura, T | 1 |
| Kojima, S | 1 |
| Taketsuna, M | 1 |
| Tomimoto, H | 1 |
| Takahashi, R | 1 |
| Fukuyama, H | 1 |
| Nagatsuka, K | 1 |
| Yamamoto, H | 1 |
| Fukushima, M | 1 |
| Ihara, M | 2 |
| Kwon, HS | 1 |
| Lee, D | 1 |
| Lee, MH | 1 |
| Yu, S | 1 |
| Lim, JS | 1 |
| Yu, KH | 1 |
| Oh, MS | 1 |
| Lee, JS | 1 |
| Hong, KS | 1 |
| Lee, EJ | 1 |
| Kang, DW | 1 |
| Kwon, SU | 1 |
| McHutchison, C | 1 |
| Blair, GW | 1 |
| Appleton, JP | 1 |
| Chappell, FM | 1 |
| Doubal, F | 1 |
| Bath, PM | 1 |
| Wardlaw, JM | 2 |
| Doubal, FN | 1 |
| Blair, G | 1 |
| Xu, T | 1 |
| Wang, Y | 1 |
| Chen, Y | 1 |
| Schaler, AW | 1 |
| Myeku, N | 1 |
| Choi, PK | 1 |
| Chung, JY | 1 |
| Lee, SJ | 1 |
| Kang, HG | 1 |
| Park, SY | 1 |
| Kim, HY | 1 |
| Lee, YS | 1 |
| Heo, HJ | 1 |
| Shin, HK | 1 |
| Lee, WS | 1 |
| Hong, KW | 1 |
| Kim, CD | 1 |
| Takata, Y | 1 |
| Kasahara, Y | 1 |
| Tsuji, M | 1 |
| Nishino, M | 1 |
| Stern, D | 1 |
| Okada, M | 1 |
1 review available for cilostazol and Cognitive Decline
| Article | Year |
|---|---|
Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis.
Topics: Cilostazol; Cognitive Dysfunction; Fibrinolytic Agents; Humans; Phosphodiesterase 3 Inhibitors; Seco | 2020 |
2 trials available for cilostazol and Cognitive Decline
| Article | Year |
|---|---|
Efficacy and Safety of Cilostazol in Mild Cognitive Impairment: A Randomized Clinical Trial.
Topics: Adult; Aged; Alzheimer Disease; Amyloid beta-Peptides; Cilostazol; Cognitive Dysfunction; Dementia; | 2023 |
Post-stroke cognitive impairment as an independent predictor of ischemic stroke recurrence: PICASSO sub-study.
Topics: Aged; Aspirin; Cilostazol; Cognitive Dysfunction; Female; Fibrinolytic Agents; Humans; Male; Middle | 2020 |
7 other studies available for cilostazol and Cognitive Decline
| Article | Year |
|---|---|
Cognitive effects of cilostazol in Alzheimer's dementia patients with peripheral arterial occlusive disease: A case-control study.
Topics: Acetylcholinesterase; Alzheimer Disease; Case-Control Studies; Cilostazol; Cognition; Cognitive Dysf | 2023 |
Response by Doubal et al to Letter Regarding Article, "Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis".
Topics: Cilostazol; Cognitive Dysfunction; Humans; Platelet Aggregation Inhibitors; Secondary Prevention; St | 2020 |
Letter by Xu et al Regarding Article, "Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis".
Topics: Cilostazol; Cognitive Dysfunction; Humans; Platelet Aggregation Inhibitors; Secondary Prevention; St | 2020 |
Cilostazol, a phosphodiesterase 3 inhibitor, activates proteasome-mediated proteolysis and attenuates tauopathy and cognitive decline.
Topics: Animals; Cilostazol; Cognitive Dysfunction; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Male; | 2018 |
Recurrent cerebral microbleeds with acute stroke symptoms: A case report.
Topics: Aged; Basal Ganglia Cerebrovascular Disease; Brain; Cerebral Hemorrhage; Cilostazol; Cognitive Dysfu | 2018 |
Augmented improvement of cognition and memory by aripiprazole add-on for cilostazol treatment in the chronic cerebral hypoperfusion mouse model.
Topics: Animals; Aripiprazole; Brain; Brain Ischemia; Carotid Stenosis; Cilostazol; Cognition; Cognitive Dys | 2019 |
Cilostazol improves cognitive function in patients with mild cognitive impairment: a retrospective analysis.
Topics: Aged; Cilostazol; Cognition; Cognitive Dysfunction; Female; Follow-Up Studies; Humans; Male; Neuropr | 2013 |